Earnings Call Summary | Medpace(MEDP.US) Q1 2024 Earnings Conference
Earnings Call Summary | Medpace(MEDP.US) Q1 2024 Earnings Conference
The following is a summary of the Medpace Holdings, Inc. (MEDP) Q1 2024 Earnings Call Transcript:
以下是Medpace Holdings, Inc.（MEDP）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Medpace reported Q1 2024 revenue of $511 million, up by 17.7% year-over-year.
The company's net income increased by 40.7% to $102.6 million compared to the prior year.
EBITDA of $115.7 million was up by 24.6% compared to the prior year.
The company had $407 million in cash, with $308.8 million remaining under a share repurchase authorization.
Medpace expects 2024 total revenue will range between $2.15 billion and $2.2 billion, signifying growth of 14% to 16.7% over 2023's total revenue.
2024 EBITDA is projected to range from $415 million to $445 million, indicating growth of 14.5% to 22.8%.
Medpace報告稱，2024年第一季度收入爲5.11億美元，同比增長17.7％。
與去年相比，該公司的淨收入增長了40.7％，達到1.026億美元。
息稅折舊攤銷前利潤爲1.157億美元，與去年同期相比增長了24.6％。
該公司擁有4.07億澳元的現金，股票回購授權下還剩3.088億美元。
Medpace預計，2024年的總收入將在21.5億美元至22億美元之間，這意味着比2023年的總收入增長14％至16.7％。
2024年的息稅折舊攤銷前利潤預計將在4.15億美元至4.45億美元之間，增長14.5％至22.8％。
Business Progress:
業務進展：
Despite Q1 bookings coming in below company projections due to increased cancellations, Medpace remains confident in its direct revenue growth of roughly 15% this year.
The company has enhanced investment productivity via automation, process improvements, and optimizing the geographical distribution of staff.
The business forecasts that around $1.56 billion of the backlog will convert to revenue in the coming 12 months.
Strategic hiring is planned to support the company's growth.
Moving IT and operations to lower-cost regions, such as Europe and India, is expected to boost productivity over time.
Medpace states the cancellations observed in this quarter were due to product performance and failed compounds, not funding concerns.
To support growth in 2025, the company is targeting a book to bill ratio between 1.22 to 1.25.
The company foresees a moderation in the inflation related to site reimbursements post COVID, hence, the effects on pass-through costs might decrease over time.
儘管由於取消人數增加，第一季度的預訂量低於公司的預期，但Medpace對其今年約15％的直接收入增長仍然充滿信心。
該公司通過自動化、流程改進和優化員工地域分配提高了投資生產率。
該企業預測，在未來12個月中，約15.6億美元的待辦事項將轉化爲收入。
計劃進行戰略招聘以支持公司的發展。
隨着時間的推移，將IT和運營轉移到較低成本的地區，例如歐洲和印度，預計將提高生產力。
Medpace表示，本季度觀察到的取消是由於產品性能和化合物失效，而不是資金問題。
爲了支持2025年的增長，該公司的目標是賬面賬單比率在1.22至1.25之間。
該公司預計，在COVID之後，與網站報銷相關的通貨膨脹將有所緩和，因此，隨着時間的推移，對直通成本的影響可能會降低。
More details: Medpace IR
更多詳情： Medpace IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。